| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Buprenorphine measurement |
Component |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine poisoning |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Accidental buprenorphine poisoning |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Intentional buprenorphine poisoning |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| intoxication par la buprénorphine d'intention indéterminée |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine adverse reaction |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Allergy to buprenorphine (finding) |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine overdose |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Accidental buprenorphine overdose |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Intentional buprenorphine overdose |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| surdose de buprénorphine d'intention indéterminée |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing buprenorphine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 400 microgram/1 each conventional release sublingual tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine (as buprenorphine hydrochloride) 2 mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 milligram/1 each conventional release sublingual tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine (as buprenorphine hydrochloride) 200 microgram sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| buprénorphine 300 microgrammes/mL, ampoule de 1 mL de solution pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 70micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 52.5micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 35micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride + naloxone hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride 2mg + naloxone hydrochloride 0.5mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine hydrochloride 8mg + naloxone hydrochloride 2mg sublingual tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Urine buprenorphine level (procedure) |
Component |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine 35micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 52.5micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 70micrograms/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Serum buprenorphine level (procedure) |
Component |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Plasma buprenorphine level (procedure) |
Component |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine hydrochloride |
Is a |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Accidental buprenorphine poisoning |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Intentional buprenorphine poisoning |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing buprenorphine and naloxone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Product containing buprenorphine in topical dosage form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Product containing buprenorphine in oropharyngeal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine-containing product in parenteral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Norbuprenorphine (substance) |
Is a |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 20 microgram/hour prolonged-release transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 10 microgram/hour prolonged-release transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Buprenorphine 5microgram/hour transdermal patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Product containing buprenorphine and naloxone in oropharyngeal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Allergy to buprenorphine (finding) |
Causative agent (attribute) |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine hydrochloride |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
|
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 400 microgram/1 each conventional release sublingual tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 8 milligram/1 each conventional release sublingual tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine (as buprenorphine hydrochloride) 200 microgram sublingual tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine (as buprenorphine hydrochloride) 2 mg sublingual tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine-containing product in transdermal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 300 microgram/1 milliliter conventional release solution for injection ampule |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 35 microgram/hour prolonged-release transdermal patch |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 35 microgram/hour prolonged-release transdermal patch |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 52.5 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 52.5 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 70 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing buprenorphine in cutaneous dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine-containing product in oromucosal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine and naloxone only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Product containing only buprenorphine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine and naloxone only product in oromucosal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine only product in cutaneous dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine only product in oromucosal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing only buprenorphine in transdermal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine (as buprenorphine hydrochloride) 300 microgram/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Allergy to buprenorphine (finding) |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 20 microgram/hour prolonged-release transdermal patch |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 20 microgram/hour prolonged-release transdermal patch |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 10 microgram/hour prolonged-release transdermal patch |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 10 microgram/hour prolonged-release transdermal patch |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 2 mg and naloxone hydrochloride 500 microgram sublingual tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine 2 mg and naloxone hydrochloride 500 microgram sublingual tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Product containing buprenorphine and naloxone in oromucosal dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Buprenorphine (as buprenorphine hydrochloride) 8 mg and naloxone hydrochloride 2 mg sublingual tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Drug addiction therapy using buprenorphine (regime/therapy) |
Using substance (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
2 |
| Drug addiction therapy using buprenorphine and naloxone |
Using substance (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
3 |
| Buprenorphine dependence (disorder) |
Causative agent (attribute) |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 5 microgram/hour prolonged-release transdermal patch |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Buprenorphine 5 microgram/hour prolonged-release transdermal patch |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 15 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely buprenorphine 15 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Serum buprenorphine level (procedure) |
Component |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Plasma buprenorphine level (procedure) |
Component |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
| Urine buprenorphine level (procedure) |
Component |
True |
Buprenorphine (substance) |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]